Predictors for the development of cholangiocarcinoma and hepatocellular carcinoma: in search for the most accurate biomarker.
作者信息
Tzovaras Alexandros A, Kamposioras Konstantinos, Ardavanis Alexandros
机构信息
1 Department of Medical Oncology, Aghios Savvas Anticancer Hospital, Athens, Greece.
出版信息
Arch Med Sci. 2011 Dec 31;7(6):925-7. doi: 10.5114/aoms.2011.26600. Epub 2011 Dec 30.
Abstract
摘要
相似文献
1
Predictors for the development of cholangiocarcinoma and hepatocellular carcinoma: in search for the most accurate biomarker.胆管癌和肝细胞癌发生的预测因素：寻找最准确的生物标志物。
Arch Med Sci. 2011 Dec 31;7(6):925-7. doi: 10.5114/aoms.2011.26600. Epub 2011 Dec 30.
2
Biomarker to distinguish hepatocellular carcinoma from cholangiocarcinoma by serum a disintegrin and metalloprotease 12.血清去整合素金属蛋白酶 12 区分肝细胞癌和胆管细胞癌的生物标志物。
Arch Med Sci. 2011 Dec 31;7(6):1013-6. doi: 10.5114/aoms.2011.26613. Epub 2011 Dec 30.
3
Current update on combined hepatocellular-cholangiocarcinoma.肝细胞胆管癌联合诊疗的最新进展
Eur J Radiol Open. 2014 Sep 6;1:40-8. doi: 10.1016/j.ejro.2014.07.001. eCollection 2014.
4
Intrahepatic Cholangiocarcinoma Cells Promote Epithelial-mesenchymal Transition of Hepatocellular Carcinoma Cells by Secreting LAMC2.肝内胆管癌细胞通过分泌LAMC2促进肝癌细胞的上皮-间质转化。
J Cancer. 2021 Apr 19;12(12):3448-3457. doi: 10.7150/jca.55627. eCollection 2021.
5
α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.甲胎蛋白阳性胃癌和肝细胞癌-胆管细胞癌混合型在形态学上相似，但在 SALL4 表达方面具有不同的组织发生。
Hum Pathol. 2012 Nov;43(11):1955-63. doi: 10.1016/j.humpath.2011.11.022. Epub 2012 Apr 17.
6
Living Donor Liver Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Experience of a Single Center.活体供肝肝移植治疗肝细胞癌合并胆管癌：单中心经验
Ann Transplant. 2017 Feb 28;22:115-120. doi: 10.12659/aot.900779.
7
A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.肝细胞癌与胆管癌合并的组织病理学研究：胆管癌成分起源于肝细胞癌。
Hepatogastroenterology. 2007 Mar;54(74):508-13.
8
The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan.台湾肝细胞癌和肝内胆管细胞癌中细胞角蛋白和 Sal-Like 蛋白 4 表达的预后价值。
Int J Med Sci. 2018 Nov 23;15(14):1746-1756. doi: 10.7150/ijms.28440. eCollection 2018.
9
Dysregulated Expression of MITF in Subsets of Hepatocellular Carcinoma and Cholangiocarcinoma.小眼畸形相关转录因子（MITF）在肝细胞癌和胆管癌亚群中的表达失调
Tohoku J Exp Med. 2017 Aug;242(4):291-302. doi: 10.1620/tjem.242.291.
10
Synchronous hepatocellular carcinoma and cholangiocarcinoma arising in two different dysplastic nodules.起源于两个不同发育异常结节的同步性肝细胞癌和胆管癌。
Mod Pathol. 2002 Oct;15(10):1096-101. doi: 10.1097/01.MP.0000027622.74779.AE.
本文引用的文献
1
Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinoma.p53 基因外显子 7 密码子 249 突变与肝细胞癌诊断的关系。
Arch Med Sci. 2010 Jun 30;6(3):348-55. doi: 10.5114/aoms.2010.14254.
2
Biomarker to distinguish hepatocellular carcinoma from cholangiocarcinoma by serum a disintegrin and metalloprotease 12.血清去整合素金属蛋白酶 12 区分肝细胞癌和胆管细胞癌的生物标志物。
Arch Med Sci. 2011 Dec 31;7(6):1013-6. doi: 10.5114/aoms.2011.26613. Epub 2011 Dec 30.
3
Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma.用于检测胆管癌的生物标志物的蛋白质组学分析与评估
Asian Pac J Cancer Prev. 2011;12(6):1503-10.
4
Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.NQO1表达在肝内胆管癌中的预后意义
Int J Clin Exp Pathol. 2011 Apr;4(4):363-70. Epub 2011 Apr 10.
5
The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.血清碳水化合物抗原（CA19-9）作为胰腺癌和胆管癌诊断工具的临床实用性和局限性。
Dig Dis Sci. 2011 Aug;56(8):2491-6. doi: 10.1007/s10620-011-1709-8. Epub 2011 Apr 23.
6
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.许多原发性硬化性胆管炎和血清碳水化合物抗原 19-9 水平升高的患者并没有胆管癌。
Clin Gastroenterol Hepatol. 2011 May;9(5):434-9.e1. doi: 10.1016/j.cgh.2011.02.007. Epub 2011 Feb 17.
7
A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score.基于肝内胆管癌临床特征的预后评分系统：复旦评分。
Ann Oncol. 2011 Jul;22(7):1644-1652. doi: 10.1093/annonc/mdq650. Epub 2011 Jan 6.
8
Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.肝内胆管癌和肝细胞癌血清肿瘤标志物的比较。
Am Surg. 2010 Nov;76(11):1210-3.
9
The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.αvβ6 整联蛋白是胆管癌的高度特异性免疫组化标志物。
J Hepatol. 2010 Mar;52(3):362-9. doi: 10.1016/j.jhep.2009.12.006. Epub 2010 Jan 13.
10
Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma.肝内胆管癌：272例患者的报告并与5829例肝细胞癌患者对比。
J Cancer Res Clin Oncol. 2009 Aug;135(8):1073-80. doi: 10.1007/s00432-009-0547-y. Epub 2009 Mar 18.
Zotero 插件